Teva Branded Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA BRANDED PHARM, and when can generic versions of TEVA BRANDED PHARM drugs launch?
TEVA BRANDED PHARM has thirty-three approved drugs.
There are fifty-nine US patents protecting TEVA BRANDED PHARM drugs.
There are six hundred and eighty patent family members on TEVA BRANDED PHARM drugs in forty-one countries and thirty-nine supplementary protection certificates in fourteen countries.
Summary for Teva Branded Pharm
International Patents: | 680 |
US Patents: | 59 |
Tradenames: | 33 |
Ingredients: | 19 |
NDAs: | 33 |
Patent Litigation for Teva Branded Pharm: | See patent lawsuits for Teva Branded Pharm |
Drugs and US Patents for Teva Branded Pharm
Expired US Patents for Teva Branded Pharm
Paragraph IV (Patent) Challenges for TEVA BRANDED PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 0.1 mg/0.02 mg and 0.01 mg | ➤ Subscribe | 2009-11-16 |
➤ Subscribe | Tablets | 0.15 mg/0.03 mg | ➤ Subscribe | 2004-03-29 |
➤ Subscribe | Tablets | 1 mg/0.02 mg and 75 mg | ➤ Subscribe | 2006-04-17 |
➤ Subscribe | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | ➤ Subscribe | 2013-07-10 |
➤ Subscribe | Tablets | 0.15 mg/0.03 mg/0.01 mg | ➤ Subscribe | 2008-01-22 |
International Patents for Teva Branded Pharm Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1223311 | ⤷ Try a Trial |
Spain | 2561491 | ⤷ Try a Trial |
South Korea | 101618933 | ⤷ Try a Trial |
Canada | 3111537 | ⤷ Try a Trial |
Israel | 247397 | ⤷ Try a Trial |
Israel | 276280 | ⤷ Try a Trial |
China | 114788824 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Branded Pharm Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1602370 | SPC/GB09/024 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: COMBINATION COMPRISING ALISKIREN, AS THE FREE BASE OR AS A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5893501 20081028; CH 5893502 20081028; CH 5893503 20081028; CH 5893504 20081028; UK EU/1/08/491/006 20090116; UK EU/1/08/491/002 20090116; UK EU/1/08/491/003 20090116; UK EU/1/08/491/004 20090116; UK EU/1/08/491/005 20090116; UK EU/1/08/491/007 20090116; UK EU/1/08/491/080 20090116; UK EU/1/08/491/074 20090116; UK EU/1/08/491/075 20090116; UK EU/1/08/491/076 20090116; UK EU/1/08/491/077 20090116; UK EU/1/08/491/078 20090116; UK EU/1/08/491/079 20090116; UK EU/1/08/491/068 20090116; UK EU/1/08/4 |
1453521 | 132016000025143 | Italy | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414 |
1214076 | SZ 49/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON |
0771217 | 07C0001 | France | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
1389098 | 2013C/054 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225 |
0771217 | CA 2006 00038 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804 |
1453521 | CA 2016 00016 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.